▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1170 by analyst upside · 2026-09-05
DYN
Dyne Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+62.3%
implied upside to consensus target
Current Price $24.28
Consensus Target $39.4
Bull Target $50.0
Bear Target $17.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
11
Hold
1
Sell
0
52-Week Low $11.92
52-Week High $27.3
YTD Return +31.2%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.92
52-Week High $27.3
Current Price $24.28
Bear Target $17.0
Bull Target $50.0
● Now $24.28 ● Target $39.4
TRADING DATA
Avg Volume 2.2M
YTD Return +31.2%
Analyst Count 15
Consensus Buy
Upside to Target +62.3%
Last Updated 2026-09-05

ANALYST SUMMARY

Dyne Therapeutics, Inc. (DYN) is currently trading at $24.28 with a Wall Street consensus price target of $39.4, implying potential upside of 62.3% over the next 12 months. 15 analysts currently cover DYN, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $17.0.

DYN operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 31.2% year-to-date and is currently trading near the upper end of its 52-week range of $11.92 – $27.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INDV +40.2%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.5x · Buy
GRFS +39.3%
Grifols, S.A.
$5B · P/E 10.3x · Buy
ACAD +21.3%
ACADIA Pharmaceuticals Inc.
$5B · P/E 12.5x · Buy
OPCH +18.1%
Option Care Health, Inc.
$4B · P/E 18.6x · Buy
CON +15.7%
Concentra Group Holdings Parent, Inc.
$4B · P/E 22.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DYN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-31 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-30 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-07-23 40% win rate (10 calls)
TD Cowen ● Initiated
Buy 2026-06-26 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-15 Building track record
Bernstein - Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-09 33% win rate (6 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-03-03 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
21/30
Consensus clarity
3/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →